4basebio AG announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was EUR 1.052 million compared to EUR 1.174 million a year ago. Net loss was EUR 2.653 million compared to EUR 301,000 a year ago. Basic loss per share from continuing operations was EUR 0.07 compared to EUR 0.06 a year ago. Basic loss per share was EUR 0.05 compared to EUR 0.01 a year ago. Diluted loss per share from continuing operations was EUR 0.06 compared to EUR 0.05 a year ago. Diluted loss per share was EUR 0.04 compared to EUR 0.01 a year ago.